Hospitalized Acute Medical Illness Patients Therapeutics
1. Bevyxxa patent expiration
Treatment: Prophylaxis of pulmonary embolism; Prophylaxis of venous thromboembolism; Inhibiting coagulation; Prophylaxis of venous thrombosis; Preventing condition characterized by undesired thrombosis
BEVYXXA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8691847 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor Xa |
Sep, 2020
(5 years ago) | |
| US6376515 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor Xa |
Sep, 2020
(5 years ago) | |
| US8518977 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor XA |
Sep, 2020
(5 years ago) | |
| US6835739 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor Xa |
Sep, 2020
(5 years ago) | |
| US7598276 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555023 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(9 months from now) | |
| US9629831 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor XA |
Sep, 2020
(5 years ago) | |
| US8404724 | PORTOLA PHARMS INC | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor |
Mar, 2031
(5 years from now) | |
| US8557852 | PORTOLA PHARMS INC | Methods of using crystalline forms of a salt of a factor Xa inhibitor |
Sep, 2028
(2 years from now) | |
| US8987463 | PORTOLA PHARMS INC | Methods of synthesizing factor Xa inhibitors |
Dec, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: 23 June, 2021
Market Authorisation Date: 23 June, 2017
Dosage: CAPSULE
More Information on Dosage
BEVYXXA family patents
